Abbott Laboratories $ABT Stock Position Increased by Absher Wealth Management LLC

Absher Wealth Management LLC grew its position in shares of Abbott Laboratories (NYSE:ABT) by 68.9% in the first quarter, Holdings Channel reports. The fund owned 333,127 shares of the healthcare product maker’s stock after buying an additional 135,846 shares during the quarter. Abbott Laboratories makes up about 4.0% of Absher Wealth Management LLC’s portfolio, making the stock its 10th biggest position. Absher Wealth Management LLC’s holdings in Abbott Laboratories were worth $34,202,000 at the end of the most recent quarter.

Several other large investors have also recently modified their holdings of the stock. Freemont Management S.A. raised its stake in shares of Abbott Laboratories by 197.2% during the fourth quarter. Freemont Management S.A. now owns 10,700 shares of the healthcare product maker’s stock worth $1,341,000 after buying an additional 7,100 shares during the last quarter. PFA Pension Forsikringsaktieselskab bought a new stake in Abbott Laboratories during the 4th quarter worth about $116,580,000. Danica Pension Livsforsikringsaktieselskab bought a new stake in Abbott Laboratories in the third quarter valued at approximately $185,640,000. Thrivent Financial for Lutherans boosted its position in Abbott Laboratories by 24.3% during the fourth quarter. Thrivent Financial for Lutherans now owns 246,586 shares of the healthcare product maker’s stock worth $30,931,000 after purchasing an additional 48,286 shares during the period. Finally, Net Worth Advisory Group acquired a new stake in Abbott Laboratories during the 4th quarter worth approximately $1,366,000. Institutional investors own 75.18% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have recently commented on ABT shares. The Goldman Sachs Group lowered their target price on shares of Abbott Laboratories from $121.00 to $113.00 and set a “buy” rating on the stock in a report on Wednesday, May 27th. Benchmark reduced their target price on shares of Abbott Laboratories from $145.00 to $120.00 and set a “buy” rating on the stock in a report on Friday, April 17th. JPMorgan Chase & Co. dropped their price target on shares of Abbott Laboratories from $123.00 to $110.00 and set an “overweight” rating on the stock in a research report on Friday, April 17th. Bank of America decreased their price target on shares of Abbott Laboratories from $120.00 to $102.00 in a research note on Friday, June 12th. Finally, Mizuho lowered their price objective on shares of Abbott Laboratories from $125.00 to $115.00 and set a “neutral” rating on the stock in a report on Friday, April 17th. Three investment analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have issued a Hold rating to the company. According to MarketBeat.com, Abbott Laboratories presently has an average rating of “Moderate Buy” and a consensus price target of $118.42.

Abbott Laboratories Stock Up 0.0%

ABT stock opened at $93.97 on Monday. The stock has a fifty day moving average of $89.21 and a 200-day moving average of $103.09. The company has a market capitalization of $163.69 billion, a price-to-earnings ratio of 26.32, a PEG ratio of 1.62 and a beta of 0.61. Abbott Laboratories has a fifty-two week low of $81.97 and a fifty-two week high of $137.49. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.01 and a current ratio of 1.39.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings data on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share for the quarter, beating analysts’ consensus estimates of $1.14 by $0.01. Abbott Laboratories had a net margin of 13.90% and a return on equity of 17.62%. The business had revenue of $11.16 billion during the quarter, compared to analyst estimates of $10.99 billion. During the same period in the previous year, the business earned $1.09 EPS. Abbott Laboratories’s revenue was up 7.8% compared to the same quarter last year. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. As a group, equities research analysts predict that Abbott Laboratories will post 5.48 earnings per share for the current year.

Abbott Laboratories Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, August 17th. Shareholders of record on Wednesday, July 15th will be issued a $0.63 dividend. This represents a $2.52 annualized dividend and a yield of 2.7%. The ex-dividend date of this dividend is Wednesday, July 15th. Abbott Laboratories’s dividend payout ratio (DPR) is presently 70.59%.

Insider Activity

In related news, Director Daniel J. Starks acquired 10,000 shares of the firm’s stock in a transaction that occurred on Monday, April 27th. The shares were bought at an average cost of $92.65 per share, for a total transaction of $926,500.00. Following the completion of the transaction, the director owned 6,751,103 shares in the company, valued at approximately $625,489,692.95. This trade represents a 0.15% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Philip P. Boudreau bought 2,200 shares of Abbott Laboratories stock in a transaction that occurred on Thursday, April 23rd. The stock was purchased at an average cost of $91.50 per share, for a total transaction of $201,300.00. Following the purchase, the chief financial officer owned 2,200 shares of the company’s stock, valued at $201,300. The trade was a ∞ increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. 0.46% of the stock is owned by insiders.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.